{"a":[{"_":"Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact","$":{"href":"/biotech/pathos-ai-pads-pipeline-22b-alphamab-deal-plus-astrazeneca-pact","hreflang":"en"}}]}

bispecific antibody-drug conjugatePositive

AI Analysis

Summary

Pathos AI agreed to acquire a bispecific antibody-drug conjugate from China's Alphamab Oncology for $125 million while establishing a partnership with AstraZeneca to expand its pipeline.

Importance:7/10

Sentiment:

0.60

acquisitionpartnershipbispecific antibodydrug conjugateoncologyChina

Related Companies

$AZN

Read the original article

Published by FierceBiotech on August 4, 2026 4:12 AM

Read Original